Jeffrey Brittan, MD
Family Medicine · North Platte, NENPI 1578591103
Payments from drug & device makers
Across 288 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$469
- Boehringer Ingelheim$406
- Novo Nordisk$372
- Amgen$333
- Pfizer$315
- AbbVie$276
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,087100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $469 |
| Boehringer Ingelheim | 30 | $406 |
| Novo Nordisk | 27 | $372 |
| Amgen(2 entities) | 24 | $333 |
| Pfizer | 40 | $315 |
| AbbVie(2 entities) | 21 | $276 |
| Johnson & Johnson | 10 | $189 |
| Astellas Pharma US Inc | 10 | $185 |
| Sanofi-aventis U.S. LLC | 12 | $184 |
| Novartis | 8 | $150 |
| Exact Sciences | 8 | $133 |
| E.r. Squibb & Sons, L.L.C. | 6 | $89 |
| Daiichi Sankyo Inc. | 5 | $88 |
| Merck | 6 | $86 |
| AstraZeneca | 6 | $84 |
| Dexcom, Inc. | 5 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| GSK | 4 | $52 |
| Gilead | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 4 | $48 |
| Organon | 2 | $46 |
| Mylan Specialty L.p. | 3 | $40 |
| Soleno Therapeutics, Inc. | 2 | $34 |
| Boston Scientific | 1 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Abbott | 1 | $24 |
| Genentech USA, Inc. | 2 | $23 |
| Eisai Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
How this compares
$4,087 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 310 | $173,658 |
| XareltoRivaroxaban | 129 | $79,326 |
| JardianceEmpagliflozin | 115 | $62,514 |
| MyrbetriqMirabegron | 116 | $35,904 |
| JanuviaSitagliptin Phosphate | 48 | $35,339 |
| Repatha SureclickEvolocumab | 45 | $31,504 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $29,917 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $26,739 |
| OzempicSemaglutide | 24 | $24,214 |
| Bydureon BciseExenatide Microspheres | 23 | $18,425 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $16,690 |
| EntrestoSacubitril/Valsartan | 20 | $14,494 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,550 |
| Pantoprazole Sodium | 689 | $11,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $315 | $173,658310 claims |
| Johnson & JohnsonXarelto | $189 | $79,326129 claims |
| Boehringer IngelheimJardiance | $406 | $62,514115 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta, Incruse Ellipta | $52 | $44,718100 claims |
| MerckJanuvia, Janumet | $86 | $38,98761 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $35,904116 claims |
| Novo NordiskOzempic | $372 | $24,21424 claims |
| NovartisEntresto | $150 | $14,49420 claims |
| AstraZenecaBrilinta | $84 | $9,35320 claims |
| Lilly USA, LLCTrulicity | $469 | $6,89311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in North Platte
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.